Similar Posts
JD.com: Valuation And Fundamentals At An Inflection Point (NASDAQ:JD)
JD.com: Valuation And Fundamentals At An Inflection Point Source link
23andMe cuts 40% of its workforce, discontinues all therapy programs By Reuters
(Reuters) -Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing further development of all its therapies as part of a restructuring program. “We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer…
Oswal Pumps set to debut today. GMP signals modest listing gain
Oswal Pumps is scheduled to make its debut on the NSE and BSE on Friday after a strong response to its Rs 1,387 crore IPO, which closed on June 17. Market participants are eyeing a listing premium of around Rs 41, going by the latest grey market premium (GMP), which indicates a possible upside of…
Journey Medical: FDA Approval For Emrosi Makes This An Exciting Stock (DERM)
Journey Medical: FDA Approval For Emrosi Makes This An Exciting Stock Source link
Trading Watch List 02.14.2025
QQQ finally coming out of range and with that bullish action all around. Follow me on X/Twitter for real time trading setups @szaman and on StockTwits @szaman. Watch us trade these stocks LIVE, in real-time. Click here to get started! Check out our watch list and game plan: If you want to learn how to trade…
